Talk:Allovectin-7

Allovectin development abandoned in 2012

"August 12, 2012; (Genetic Engineering and Biotechnology News) -- Vical said today it would end development of its lead drug Allovectin® (velimogene aliplasmid) for metastatic melanoma after the investigational intratumoral cancer immunotherapy failed to meet efficacy endpoints in a Phase-III clinical trial. Vical said that it would refocus its development efforts on vaccines for infectious diseases. The company said Allovectin failed to demonstrate statistically significant improvement vs. first-line chemotherapy for either the primary endpoint of objective response rate at 24 weeks or more after randomization, or the secondary endpoint of overall survival, in the 390-patient trial. Data from the trial will be further analyzed, with detailed results to be submitted for publication at an unspecified time. " - Rod57 (talk) 12:51, 17 November 2014 (UTC)